Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode

EGFR T790M mutation accounts for about 40-55% drug resistance for the first generation EGFR kinase inhibitors in the NSCLC. Starting from ibrutinib, a highly potent irreversible BTK kinase inhibitor, which was also found to be moderately active to EGFR T790M mutant, we discovered a highly potent irr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chen, Wang, Aoli, Wu, Hong, Qi, Ziping, Li, Xixiang, Yan, Xiao-E, Chen, Cheng, Yu, Kailin, Zou, Fengming, Wang, Wenchao, Wang, Wei, Wu, Jiaxin, Liu, Juan, Wang, Beilei, Wang, Li, Ren, Tao, Zhang, Shanchun, Yun, Cai-Hong, Liu, Jing, Liu, Qingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392334/
https://www.ncbi.nlm.nih.gov/pubmed/28407693
http://dx.doi.org/10.18632/oncotarget.15443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392334/
https://www.ncbi.nlm.nih.gov/pubmed/28407693
http://dx.doi.org/10.18632/oncotarget.15443

Ejemplares similares